Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

In a letter, researchers report data (n=250), which together with epidemiological data of B.1.617.2 (India) growth, raise possibility this Variant of Concern presents dual challenge of reduced vaccine efficacy akin to B.1.351 (S Africa) & increased transmissibility beyond B.1.1.7

Source:

The Lancet